Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.38 |
| ▸ | HTR2A | P28223 | 6/20 | 0.38 |
| ▸ | HTR2B | P41595 | 3/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.32 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL251263 | 1.00 | HTR2C (0.38) | HTR2CHTR2AHTR2BCYP1A1MTNR1A | |
| SCHEMBL705701 | 0.90 | HTR2C (0.41) | HTR2CHTR2AHTR2BCYP1A1MTNR1A | |
| SCHEMBL436034 | 0.90 | HTR2C (0.41) | HTR2CHTR2AHTR2BCYP1A1MTNR1A | |
| SCHEMBL6866823 | 0.81 | TYR (0.42) | HTR2CCYP1A1ALOX5 | |
| SCHEMBL251633 | 0.77 | HTR2A (0.37) | HTR2CHTR2AHTR2BALOX5LTB4R | |
| SCHEMBL7934677 | 0.77 | HTR2A (0.37) | HTR2CHTR2AHTR2BALOX5LTB4R | |
| SCHEMBL1525666 | 0.77 | HTR2A (0.37) | HTR2CHTR2AHTR2BALOX5LTB4R | |
| SCHEMBL250560 | 0.77 | HTR2A (0.37) | HTR2CHTR2AHTR2BALOX5LTB4R | |
| SCHEMBL3262720 | 0.77 | HTR2A (0.37) | HTR2CHTR2AHTR2BALOX5LTB4R | |
| SCHEMBL9720820 | 0.76 | HTR2C (0.35) | HTR2CHTR2AHTR2BCYP1A1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663183-B1 | SOLID PHARMACEUTICAL DOSAGE FORM COMPRISING RITONAVIR | ABBOTT LAB (US) | 2011-07-13 | — | — | EP | claimed |
| EP-2283844-A1 | A solid pharmaceutical dosage formulation comprising lopinavir | Abbott Laboratories (US) | 2011-02-16 | — | — | EP | claimed |
| US-20110015216-A1 | Solid Pharmaceutical Dosage Form | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | claimed |
| US-20110008430-A1 | Solid Pharmaceutical Dosage Form | ABBOTT LABORATORIES (US) | 2011-01-13 | — | — | US | claimed |
| EP-2444070-A1 | Tablets | Abbott Laboratories (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20120022089-A1 | Solid Pharmaceutical Dosage Form | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2389172-A1 | ABUSE RESISTANT MELT EXTRUDED FORMULATION HAVING REDUCED ALCOHOL INTERACTION | Abbott Gmbh & Co., Kg (DE) | 2011-11-30 | — | — | EP | disclosed |
| EP-2386293-A1 | Process for producing a solid dispersion of an active ingredient | Abbott GmbH & Co. KG (DE) | 2011-11-16 | — | — | EP | disclosed |
| EP-1996163-B1 | PROCESS FOR PRODUCING A SOLID DISPERSION OF AN ACTIVE INGREDIENT | ABBOTT GMBH & CO KG (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-8039353-B2 | Semiconductor device and manufacturing method of semiconductor device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| US-8025899-B2 | Solid pharmaceutical dosage form | ABBOTT LABORATORIES (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110229526-A1 | FORMULATIONS OF NONOPIOID AND CONFINED OPIOID ANALGESICS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-09-22 | — | — | US | disclosed |
| WO-2011112558-A2 | SOLID COMPOSITIONS | ABBOTT LABORATORIES (US) | 2011-09-15 | — | — | WO | disclosed |
| EP-1663183-B1 | SOLID PHARMACEUTICAL DOSAGE FORM COMPRISING RITONAVIR | ABBOTT LAB (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2011068723-A1 | ABUSE RESISTANT MELT EXTRUDED FORMULATION HAVING REDUCED ALCOHOL INTERACTION | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| EP-2283844-A1 | A solid pharmaceutical dosage formulation comprising lopinavir | Abbott Laboratories (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20110015216-A1 | Solid Pharmaceutical Dosage Form | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110008430-A1 | Solid Pharmaceutical Dosage Form | ABBOTT LABORATORIES (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100021540-A1 | Tablets and Preparation Thereof | ABBOTT LABORATORIES (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021540-A1 | Tablets and Preparation Thereof | GRN, EXOSC9, ALG3 | HTR2C 3793/4885HTR2A 2438/4885HTR2B 2516/4885 |
| US-20110229526-A1 | FORMULATIONS OF NONOPIOID AND CONFINED OPIOID ANALGESICS | OPRK1, OPRL1, SIGMAR1 | HTR2C 68/4885HTR2A 89/4885HTR2B 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.